Novartis Oncology

Featured Drug Company Program


Novartis: Patient Assistance Now

800-245-5356
www.patientassistancenow.com

Novartis: Patient Assistance Now Oncology

800-282-7630
www.oncologyaccessnow.com

Novartis Oncology provides a full range of patient assistance resources and support services, through its Patient Assistance Now Oncology (PANO), Novartis Patient Assistance Foundation (PAF), and Co-pay Assistance programs.

The PANO platform is a comprehensive oncology resource that provides information on patient assistance, including reimbursement and support programs. These support options include insurance verification, education on Medicare, and information about financial assistance and free medication programs.

For a list of oncology medicines and their support services from Novartis Pharmaceuticals see the Table.

Table Novartis Oncology/Oncology Supportive Care Drugs
Drug Indications Patient support programs Contact information
Afinitor
(everolimus)
Advanced HR-positive breast cancer; HER2-negative breast cancer; advanced kidney cancer; advanced pancreatic neuroendocrine tumors of gastrointestinal or lung origin; renal angiomyolipoma with TSC; subependymal giant-cell astrocytoma with TSC Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=afinitor
Patient Assistance Now Oncology www.patientassistancenow.com
Arranon
(nelarabine)
T-cell acute lymphoblastic leukemia; T-cell lymphoblastic lymphoma Patient Assistance Now Oncology www.patientassistancenow.com
Arzerra
(ofatumumab)
Recurrent or progressive chronic lymphocytic leukemia Patient Assistance Now Oncology www.patientassistancenow.com
Exjade
(deferasirox)
Chronic iron overload caused by blood transfusions Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=exjade
Patient Assistance Now Oncology www.patientassistancenow.com
Exjade Patient Assistance and Support Services www.us.exjade.com/patient/financial-assistance.jsp
Farydak
(panobinostat)
Multiple myeloma, in combination with bortezomib and dexamethasone Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=farydak
Patient Assistance Now Oncology www.patientassistancenow.com
Gleevec
(imatinib mesylate)
Ph+ chronic myeloid leukemia;
Ph+ acute lymphoblastic leukemia; myelodysplastic or myeloproliferative diseases; aggressive systemic mastocytosis; hypereosinophilic syndrome and/or chronic eosinophilic leukemia; unresectable, recurrent, and/or metastatic dermatofibrosarcoma protuberans; CD117-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors
Gleevec Patient Support Program www.gleevec.com/patient/patient-support-program/registration.jsp
Gleevec $10 Co-Pay Card
Hycamtin capsules
(topotecan)
Relapsed small-cell lung cancer Patient Assistance Now Oncology www.patientassistancenow.com
Hycamtin for injection
(topotecan hydrochloride)
Metastatic carcinoma of the ovary;
small-cell lung cancer; recurrent or persistent carcinoma of the cervix
Patient Assistance Now Oncology www.patientassistancenow.com
Jadenu
(defarasirox) tablets
Chronic iron overload caused by blood transfusions Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=jadenu
Patient Assistance Now Oncology www.patientassistancenow.com
Mekinist
(trametinib)
Also in combination with Tafinlar
Unresectable or metastatic melanoma with BRAF V600E or V600K mutation Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=mekinist
Patient Assistance Now Oncology www.patientassistancenow.com
Odomzo
(sonidegib)
Locally advanced basal-cell carcinoma Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=odomzo
Patient Assistance Now Oncology www.patientassistancenow.com
Promacta
(eltrombopag)
Chronic immune (idiopathic) thrombocytopenia; severe aplastic anemia Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=promacta
Patient Assistance Now Oncology www.patientassistancenow.com
Sandostatin LAR Depot
(octreotide acetate for injectable suspension)
Severe diarrhea/flushing episodes in metastatic carcinoid or VIP-secreting tumors; acromegaly Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=sandostatin
Patient Assistance Now Oncology www.patientassistancenow.com
Tafinlar
(dabrafenib)
Also in combination with Mekinist
Unresectable or metastatic melanoma with BRAF V600E or V600K mutation Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=tafinlar
Patient Assistance Now Oncology www.patientassistancenow.com
Tasigna
(nilotinib)

Ph+ chronic myeloid leukemia Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=tasigna
Patient Assistance Now Oncology www.patientassistancenow.com
Tykerb
(lapatinib)
HER2/neu advanced or metastatic
breast cancer
Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=tykerb
Patient Assistance Now Oncology www.patientassistancenow.com
Votrient
(pazopanib)
Advanced renal-cell carcinoma; advanced soft-tissue sarcoma Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=votrient
Patient Assistance Now Oncology www.patientassistancenow.com
Zometa
(zoledronic acid)
Bone loss caused by cancer Patient Assistance Now Oncology www.patientassistancenow.com
Zykadia
(ceritinib)
Metastatic non–small-cell lung cancer with ALK mutation Universal Co-Pay Program www.copay.novartisoncology.com/eligibility/?name=zykadia
Patient Assistance Now Oncology www.patientassistancenow.com
HR indicates hormone receptor; Ph+, Philadelphia chromosome–positive; TSC, tuberous sclerosis complex; VIP, vasoactive intestinal peptide.

For more information about PANO visit www.oncologyaccessnow.com. Support services include:

  • Novartis Patient Assistance Foundation
    Patients with financial hardship who have no third-party insurance coverage for their Novartis medicines may be eligible to receive the drugs at no cost
  • Universal Co-Pay Program
    Patients with commercial insurance or patients paying cash without government-funded insurance may be eligible for copay assistance.
Patients and providers can call 800-282-7630 for assistance with the reimbursement process for Novartis Oncology drugs. Services include insurance benefits and coverage verification, copayment clarifications, assistance with coding and billing questions, denials and appeals support, as well as alternative funding searches and referrals to Novartis Oncology brand-specific copay card programs and independent assistance programs for low-income, uninsured patients.

Eligibility

Novartis Patient Assistance Foundation

To be eligible for the Novartis PAF, patients must:

  • Be a resident of the United States
  • Provide proof of income and meet income criteria, which varies by medication
  • Not have private or government-sponsored insurance.
Depending on the prescribed Novartis medication, financial eligibility requirements for the Novartis PAF are 250% to 500% of the federal poverty level.

Universal Co-Pay Program

The specific requirements vary by medication. Patients must:

  • Be commercially insured
  • Not have private or government-sponsored insurance
  • Be a resident of the United States or Puerto Rico
  • Be prescribed a qualifying Novartis medication.
Eligible patients pay no more than $0 to $25 monthly out of pocket; the maximum annual benefit varies by medication.

Application & Enrollment

Novartis Patient Assistance Foundation

The enrollment process varies by medication. To learn more about the application process for a specific prescribed medication, visit www.pharma.us.novartis.com/info/patient-assistance/patient-assistance-enrollment.jsp. By selecting the medication from the drop-down menu, applicants can access enrollment information that is specific to the particular drug.

For more information about the program, patients, caregivers, and physicians can register at www.pharma.us.novartis.com/info/patient-assistance/patient-assistance-enrollment.jsp, or call 800-277-2254. Patients must re-enroll for the patient assistance program annually.

Universal Co-Pay Program

Enrollment for copay assistance is also medication-specific. In some cases, a copay card can be downloaded and printed from the drug’s website; for some drugs, patients may be required to complete a copay assistance enrollment form and provide it to the specialty pharmacy.

Receiving Novartis Medications

Novartis Patient Assistance Foundation

Patients who qualify for PAF are eligible to receive assistance for up to 1 year, or until they become eligible to receive a prescription drug benefit. Up to a 1-year supply of a medication can be shipped to the patient or to the prescribing physician.

Universal Co-Pay Program

To receive their prescribed medication, patients can present their copay card with a valid prescription to any participating pharmacy or can order their drug via mail order.